Alliance Global Partners analyst Matthew Venezia re-initiated coverage of Pluri (PLUR) with a Buy rating and $12 price target The company has transitioned from a clinical-stage cell therapy biotech with some novel bioreactor technology to a diversified biotech applying its “differentiated” bioreactor technology in multiple fields, the analyst tells investors in a research note. The firm says Pluri’s bioreactor system which solves many issues with current bioreactors related to scale up and production of cell-based products.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLUR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue